H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of Avadel Pharmaceuticals (AVDL) with a Buy rating and $22 price target The firm believes Avadel could exceed 4,000 narcolepsy patients on therapy by the end of next year. The company company is positioned to achieve the upper end of its guidance range this year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel announces appeals court decision upholding FDA approval of LUMRYZ
- Avadel Under Fire as Activist Investor Seeks to Unthrone the Board
- Avadel Pharmaceuticals Wins Appeal on LUMRYZ Approval
- Avadel Pharmaceuticals: Promising Outlook with Orphan Drug Designation and Market Expansion for LUMRYZ
- Avadel Pharmaceuticals Receives FDA Orphan Drug Designation